Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Second Continuous Marketing Application Pilot Program Nearly 50% Enrolled

This article was originally published in The Pink Sheet Daily

Executive Summary

Nine divisions have not yet selected their application for the pilot program, which involves frequent scientific feedback and interactions with FDA during the IND phase of product development. Applications are being accepted through the end of September.

You may also be interested in...



HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down

Human Genome Sciences plans to reduce its headcount by 20% and limit the number of drugs in early development. In 2004 and 2005, the company will focus on five products in immunology/infectious disease and oncology.

HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down

Human Genome Sciences plans to reduce its headcount by 20% and limit the number of drugs in early development. In 2004 and 2005, the company will focus on five products in immunology/infectious disease and oncology.

Millennium Prostate Cancer Agent Selected For FDA Continuous Marketing Application Pilot

The monoclonal antibody-linked chemotherapeutic MLN2704 is in a Phase I/II study for metastatic androgen-independent prostate cancer.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel